Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

Azithromycin: some indications refined and others removed due to increased bacterial resistance

 Marketing Authorisations  Due to an increase in bacterial resistance to azithromycin, the European Medicines Agency has reviewed the harm-benefit balance of this macrolide antibiotic. As a result, certain indications have been refined, some have been removed, and warnings about the risk of bacterial resistance have been added. Rational measures for an antibiotic that is useful in a variety of situations.
Full article available for download by subscribers

 ©Prescrire 1 March 2026

Source: "Azithromycin: some indications refined and others removed due to increased bacterial resistance" Prescrire Int 2026; 35 (279): 72-73. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information